Stockscreener 앱 받기
18.75
33.36%
4.69
시장 영업 전:
18.17
-0.58
-3.09%
Viridian Therapeutics Inc 주식(VRDN)의 최신 뉴스
Viridian Therapeutics’ stock up 35% after Phase III TED data release - Clinical Trials Arena
Viridian Therapeutics (NASDAQ: VRDN) files $150M convertible note offering; REVEAL‑2 topline wins - Stock Titan
RBC Capital raises Viridian Therapeutic stock price target to $34 on trial data - Investing.com
Viridian Therapeutics REVEAL-2 Hits Phase 3 Endpoint, Shows “IV-like” Proptosis Gains in Chronic TED - Yahoo Finance
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock - BioSpace
5 Stocks Turning Heads With Double-Digit Gains - Insider Monkey
Viridian (VRDN) Climbs 33% on Looming Drug Commercialization - Insider Monkey
Viridian Therapeutics (VRDN) price target decreased by 11.71% to 36.18 - MSN
Viridian’s Reveal-2 beats expectations with elegrobart in TED - BioWorld News
Viridian soars on top-line phase 3 data for elegrobart in thyroid eye disease - Seeking Alpha
Viridian’s Subcutaneous TED Treatment Passes Second Phase III Test - Citeline News & Insights
Viridian Therapeutics launches $250 million capital raise By Investing.com - Investing.com Canada
Viridian Therapeutics launches $250 million capital raise - Investing.com
Viridian eye disease drug surpasses expectations in late-stage trial; shares soar - Reuters
PDUFA decision nears as Viridian Therapeutics (VRDN) advances TED pipeline and reports Q1 results - MSN
Jefferies raises Viridian Therapeutic stock price target on trial data - Investing.com
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $32 - Moomoo
VRDN: Veligrotug and elegrobart show strong efficacy in TED, with launch readiness and pipeline expansion - TradingView
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress - BioSpace
Positive top-line Phase III results for Viridian’s elegrobart - The Pharma Letter
Viridian’s elegrobart meets primary endpoint in chronic TED trial By Investing.com - Investing.com South Africa
Viridian Therapeutics : REVEAL-2 Phase 3 Topline Results (Presentation) - marketscreener.com
Viridian’s elegrobart meets primary endpoint in chronic TED trial - Investing.com UK
PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results - Yahoo Finance
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market - Benzinga
VRDN Stock Reassessed As Analysts Cut Targets But Stay Bullish - timothysykes.com
Viridian Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Viridian Therapeutics stock surges on positive trial results By Investing.com - Investing.com Canada
Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease - TipRanks
MSN Money - MSN
Elegrobart boosts Viridian (NASDAQ: VRDN) with strong Phase 3 TED trial win - Stock Titan
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q1 Revenue $141,000 - marketscreener.com
Viridian Therapeutics (VRDN) deepens Q1 loss as late‑stage TED drugs progress - Stock Titan
Viridian (NASDAQ: VRDN) posts Q1 loss and advances TED drug approvals - Stock Titan
BRIEF-Viridian Therapeutics Q1 Revenue USD 6 Thousand Vs. IBES Estimate USD 27.5 Thousand - TradingView
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire
Why (VRDN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Jennison Associates LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Pictet Asset Management Holding SA Sells 126,618 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Viridian Therapeutics stock is tanking. Why the drop is linked to this Amgen study. - MSN
VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal? - MSN
Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN) - Insider Monkey
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease - MSN
CapEx per share of Viridian Therapeutics, Inc. – FWB:1S1 - TradingView
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know - AOL.com
Understanding Momentum Shifts in (VRDN) - Stock Traders Daily
Kopp Family Office Sells 117878 Shares of Viridian Therapeutics - HarianBasis.co
Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year - Insider Monkey
0.14%
0.48%
자본화:
|
볼륨(24시간):